Arcutis (NASDAQ: ARQT) CFO gets RSU, option grants and sells shares
Rhea-AI Filing Summary
Arcutis Biotherapeutics, Inc. SVP and Chief Financial Officer Latha Vairavan reported both stock awards and small share sales. On February 27, 2026, she received grants of 27,000 Restricted Stock Units (RSUs), each convertible into one common share, vesting 25% annually starting March 1, 2027, and a stock option for 70,000 shares that vests monthly over four years from March 1, 2026.
On March 2, 2026, she sold a total of 2,853 common shares in open‑market transactions at weighted average prices of $25.1605 and $25.9140 per share, in price ranges disclosed in the footnotes, to cover tax‑withholding obligations upon RSU vesting. After these sales, she directly held 87,754 common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 2,853 shares ($71,844)
Net Sell
4 txns
Insider
Vairavan Latha
Role
SVP Chief Financial Officer
Sold
2,853 shs ($72K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,772 | $25.1605 | $70K |
| Sale | Common Stock | 81 | $25.914 | $2K |
| Grant/Award | Stock Option (right to buy) | 70,000 | $0.00 | -- |
| Grant/Award | Common Stock | 27,000 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 87,835 shares (Direct);
Stock Option (right to buy) — 70,000 shares (Direct)
Footnotes (1)
- Constitute Restricted Stock Units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting, in which 25% of the RSUs vest annually on March 1, (the "Vesting Commencement Date"), of each year beginning March 1, 2027, subject to the Reporting Person's continued service to the Issuer. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.69 to $25.67, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.70 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. 1/48th of the shares subject to the option vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did ARQT CFO Latha Vairavan report on this Form 4?
The filing shows Latha Vairavan received stock awards and sold shares. She was granted 27,000 RSUs and a 70,000-share stock option, and sold 2,853 common shares mainly to cover tax withholding tied to RSU vesting.
What equity awards did the ARQT CFO receive according to this Form 4 filing?
The ARQT CFO received 27,000 Restricted Stock Units and a stock option for 70,000 shares. RSUs vest 25% annually starting March 1, 2027, while one forty-eighth of the option vests monthly from March 1, 2026, over four years.
How do the RSUs granted to the ARQT CFO vest over time?
The 27,000 RSUs vest in four equal annual installments. Twenty-five percent of the RSUs vest each March 1, beginning March 1, 2027, provided the CFO continues to serve Arcutis Biotherapeutics throughout the vesting period.